NCT02070094 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Ado-Trastuzumab Emtansine(T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer (NCT02070094)

Trial Description
The purpose of this study was whether the combination of two different drugs – is safe Trastuzumab Emtansine (T-DM1) (Kadcyla®; Genentech, Inc.) and ABT- 737 , and if it can be effective in treating breast cancer.

This trial is sponsored by Ukrainian Anti Cancer Institute. [1]

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
  • Phase: I & II
  • Enrollment: 0
  • Start: October 2013
  • Estimated Completion: September 2015
  • Last verified: February 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map

* ABT 737 is a novel and highly potent small molecule inhibitor of Bcl-2, a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. Bcl-2 overexpression is also associated with an increased risk of local recurrence in patients with early stage breast cancer. [2]

A number of trials have shown that by targeting the anti-apoptotic proteins Bcl-2 and Bcl-xL with ABT-737 in breast cancer the acquired radioresistance of MDA-MB-231R cells in vitro and in vivo may be reversed. These findings suggest an attractive strategy for overcoming the acquired radioresistance of breast cancer cells. [3]

Last Editorial review: July 27, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.